[Hormone therapy in prostate cancer: clinical results]

Palliative hormonotherapy is the choice treatment for disseminated prostatic cancer. The response rate oscillates between 80% and 90% and the mean probability of life expectancy exceeds two years with a substantial improvement in life quality. Hormone dependence of prostate cancer depends as a last instance on the existence of cellular clones with different sensitivity. Finally, the serial monitoring with the specific prostatic antigen allows an objectivation of the response and the early detection of the hormone refractory status.